Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pemetrexed in previously treated non-small-cell lung cancer.
Rosell R, Sanchez JM, Taron M, Moran T, Ciuraqui B, Canela M, Felip E, Massuti B, Camps C. Rosell R, et al. Among authors: moran t. Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):63-71. Oncology (Williston Park). 2004. PMID: 15339062 Review.
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ. Rosell R, et al. Among authors: moran t. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):70-6. Oncology (Williston Park). 2004. PMID: 15655942 Free article. Review.
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T. Taron M, et al. Among authors: moran t. Clin Cancer Res. 2005 Aug 15;11(16):5878-85. doi: 10.1158/1078-0432.CCR-04-2618. Clin Cancer Res. 2005. PMID: 16115929
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S; Spanish Lung Cancer Group. Ramirez JL, et al. Among authors: moran t. J Clin Oncol. 2005 Dec 20;23(36):9105-12. doi: 10.1200/JCO.2005.02.2905. J Clin Oncol. 2005. PMID: 16361617
Applications of genomics in NSCLC.
Rosella R, Cobo M, Isla D, Miguel Sanchez J, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniza O. Rosella R, et al. Among authors: moran t. Lung Cancer. 2005 Dec;50S2:S33-S40. Lung Cancer. 2005. PMID: 16551521
Applications of genomics in NSCLC.
Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O. Rosell R, et al. Among authors: moran t. Lung Cancer. 2005 Dec;50 Suppl 2:S33-40. Lung Cancer. 2005. PMID: 16557672 Review.
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, Taron M, Abad A. Martinez-Balibrea E, et al. Among authors: moran t. Oncol Rep. 2007 Mar;17(3):637-45. Oncol Rep. 2007. PMID: 17273745
1,141 results